375 related articles for article (PubMed ID: 20026769)
1. LIM and cysteine-rich domains 1 regulates cardiac hypertrophy by targeting calcineurin/nuclear factor of activated T cells signaling.
Bian ZY; Huang H; Jiang H; Shen DF; Yan L; Zhu LH; Wang L; Cao F; Liu C; Tang QZ; Li H
Hypertension; 2010 Feb; 55(2):257-63. PubMed ID: 20026769
[TBL] [Abstract][Full Text] [Related]
2. COX-2 is involved in ET-1-induced hypertrophy of neonatal rat cardiomyocytes: role of NFATc3.
Li H; Gao S; Ye J; Feng X; Cai Y; Liu Z; Lu J; Li Q; Huang X; Chen S; Liu P
Mol Cell Endocrinol; 2014 Feb; 382(2):998-1006. PubMed ID: 24291639
[TBL] [Abstract][Full Text] [Related]
3. Reciprocal repression between microRNA-133 and calcineurin regulates cardiac hypertrophy: a novel mechanism for progressive cardiac hypertrophy.
Dong DL; Chen C; Huo R; Wang N; Li Z; Tu YJ; Hu JT; Chu X; Huang W; Yang BF
Hypertension; 2010 Apr; 55(4):946-52. PubMed ID: 20177001
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin-nuclear factor of activated T cells pathway-dependent cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for atrial and brain natriuretic peptides.
Tokudome T; Horio T; Kishimoto I; Soeki T; Mori K; Kawano Y; Kohno M; Garbers DL; Nakao K; Kangawa K
Circulation; 2005 Jun; 111(23):3095-104. PubMed ID: 15939815
[TBL] [Abstract][Full Text] [Related]
5. Decreased KCNE2 Expression Participates in the Development of Cardiac Hypertrophy by Regulation of Calcineurin-NFAT (Nuclear Factor of Activated T Cells) and Mitogen-Activated Protein Kinase Pathways.
Liu W; Deng J; Ding W; Wang G; Shen Y; Zheng J; Zhang X; Luo Y; Lv C; Wang Y; Chen L; Yan D; Boudreau RL; Song LS; Liu J
Circ Heart Fail; 2017 Jun; 10(6):. PubMed ID: 28611128
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of myofibrillogenesis regulator-1 aggravates cardiac hypertrophy induced by angiotensin II in mice.
Li HL; She ZG; Li TB; Wang AB; Yang Q; Wei YS; Wang YG; Liu DP
Hypertension; 2007 Jun; 49(6):1399-408. PubMed ID: 17420335
[TBL] [Abstract][Full Text] [Related]
7. Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.
Grebe C; Klingebiel TM; Grau SP; Toischer K; Didié M; Jacobshagen C; Dullin C; Hasenfuss G; Seidler T
Cardiovasc Res; 2011 Jun; 90(3):521-8. PubMed ID: 21273244
[TBL] [Abstract][Full Text] [Related]
8. PICOT attenuates cardiac hypertrophy by disrupting calcineurin-NFAT signaling.
Jeong D; Kim JM; Cha H; Oh JG; Park J; Yun SH; Ju ES; Jeon ES; Hajjar RJ; Park WJ
Circ Res; 2008 Mar; 102(6):711-9. PubMed ID: 18258855
[TBL] [Abstract][Full Text] [Related]
9. Lmcd1/Dyxin, a novel Z-disc associated LIM protein, mediates cardiac hypertrophy in vitro and in vivo.
Frank D; Frauen R; Hanselmann C; Kuhn C; Will R; Gantenberg J; Füzesi L; Katus HA; Frey N
J Mol Cell Cardiol; 2010 Oct; 49(4):673-82. PubMed ID: 20600098
[TBL] [Abstract][Full Text] [Related]
10. TAK1 Regulates Myocardial Response to Pathological Stress via NFAT, NFκB, and Bnip3 Pathways.
Li L; Chen Y; Li J; Yin H; Guo X; Doan J; Molkentin JD; Liu Q
Sci Rep; 2015 Nov; 5():16626. PubMed ID: 26564789
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-328 as a regulator of cardiac hypertrophy.
Li C; Li X; Gao X; Zhang R; Zhang Y; Liang H; Xu C; Du W; Zhang Y; Liu X; Ma N; Xu Z; Wang L; Chen X; Lu Y; Ju J; Yang B; Shan H
Int J Cardiol; 2014 May; 173(2):268-76. PubMed ID: 24631114
[TBL] [Abstract][Full Text] [Related]
12. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.
Wilkins BJ; Dai YS; Bueno OF; Parsons SA; Xu J; Plank DM; Jones F; Kimball TR; Molkentin JD
Circ Res; 2004 Jan; 94(1):110-8. PubMed ID: 14656927
[TBL] [Abstract][Full Text] [Related]
13. Targeted disruption of Hspa4 gene leads to cardiac hypertrophy and fibrosis.
Mohamed BA; Barakat AZ; Zimmermann WH; Bittner RE; Mühlfeld C; Hünlich M; Engel W; Maier LS; Adham IM
J Mol Cell Cardiol; 2012 Oct; 53(4):459-68. PubMed ID: 22884543
[TBL] [Abstract][Full Text] [Related]
14. Activation of Na+/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure.
Nakamura TY; Iwata Y; Arai Y; Komamura K; Wakabayashi S
Circ Res; 2008 Oct; 103(8):891-9. PubMed ID: 18776042
[TBL] [Abstract][Full Text] [Related]
15. Cardiac-Specific EPI64C Blunts Pressure Overload-Induced Cardiac Hypertrophy.
Zhu X; Fang J; Gong J; Guo JH; Zhao GN; Ji YX; Liu HY; Wei X; Li H
Hypertension; 2016 May; 67(5):866-77. PubMed ID: 27021007
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of calmodulin induces cardiac hypertrophy by a calcineurin-dependent pathway.
Obata K; Nagata K; Iwase M; Odashima M; Nagasaka T; Izawa H; Murohara T; Yamada Y; Yokota M
Biochem Biophys Res Commun; 2005 Dec; 338(2):1299-305. PubMed ID: 16256941
[TBL] [Abstract][Full Text] [Related]
17. Cytosolic CARP promotes angiotensin II- or pressure overload-induced cardiomyocyte hypertrophy through calcineurin accumulation.
Chen C; Shen L; Cao S; Li X; Xuan W; Zhang J; Huang X; Bin J; Xu D; Li G; Kitakaze M; Liao Y
PLoS One; 2014; 9(8):e104040. PubMed ID: 25089522
[TBL] [Abstract][Full Text] [Related]
18. Lercanidipine attenuates angiotensin II-induced cardiomyocyte hypertrophy by blocking calcineurin-NFAT3 and CaMKII-HDAC4 signaling.
Chen Y; Yuan J; Jiang G; Zhu J; Zou Y; Lv Q
Mol Med Rep; 2017 Oct; 16(4):4545-4552. PubMed ID: 28849081
[TBL] [Abstract][Full Text] [Related]
19. Targeted inhibition of p38 MAPK promotes hypertrophic cardiomyopathy through upregulation of calcineurin-NFAT signaling.
Braz JC; Bueno OF; Liang Q; Wilkins BJ; Dai YS; Parsons S; Braunwart J; Glascock BJ; Klevitsky R; Kimball TF; Hewett TE; Molkentin JD
J Clin Invest; 2003 May; 111(10):1475-86. PubMed ID: 12750397
[TBL] [Abstract][Full Text] [Related]
20. The novel cardiac z-disc protein CEFIP regulates cardiomyocyte hypertrophy by modulating calcineurin signaling.
Dierck F; Kuhn C; Rohr C; Hille S; Braune J; Sossalla S; Molt S; van der Ven PFM; Fürst DO; Frey N
J Biol Chem; 2017 Sep; 292(37):15180-15191. PubMed ID: 28717008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
